The combination treatment proved to have enhanced anti-melanoma effect expressed as increased reduction in cell proliferation (A375 and B16F10), decreased expression of tyrosinase via the MAPK pathway (A375) and lowered expression of tyrosinase and cyclooxygenase-2 (COX-2) via the p38 kinase pathway (B16F10) [62]. This evidence concerns the gene PTGS2 and melanoma.